There is a controversy over the effectiveness of the Astrazekeca corona vaccine inoculation for the elderly abroad. The photo is the Oxford University AstraZeneca logo and vaccine taken last November in Paris, France. Paris AFP=Yonhap News
For the UK-made AstraZeneca (AZ) vaccine, which is a controversial vaccination effect for the elderly in Germany and France, the Ministry of Food and Drug Safety has concluded that there is virtually no problem with vaccination for the elderly. Many of the advisory groups concluded that administration to the elderly cannot be ruled out due to the fact that overseas clinical trials have confirmed the preventive effect in all subjects including 65 years of age or older, and that the immune response after vaccine administration is similar to that of adults. Explained. Although discussions of the Central Pharmacy Review Committee and the Final Inspection Committee remain, it is expected that domestic AZ vaccine vaccination for the elderly will be allowed if there are no variables as long as experts have passed the first gate.
The effectiveness and safety issues of the AZ vaccine have been a concern for the very first time. Vaccinations to the general public, such as those over 65 years old (about 8.5 million people), begin in earnest in May because the AZ vaccine comes in faster than other vaccines such as Modena and Janssen. As the safety controversy over vaccinations for the elderly has been settled in the first place, in order to achieve collective immunity in November, the government must conduct a preliminary inspection and plan execution.
It is no exaggeration to say that the success or failure of vaccination depends on how much the government gives the people the confidence in the safety of the vaccine. As some of the advisory groups have indicated that additional results such as clinical trials need to be confirmed, the government should closely monitor overseas adverse events in which vaccination is in progress, and come up with alternatives to promptly respond, such as changing the vaccination ranking, if any variables such as safety issues arise do. It goes without saying the need for transparent disclosure of relevant information.
Anxiety about the supply and demand of vaccines should also be resolved. As the speed of vaccine production slows,’vaccine nationalism’ is rising, with the recent European Union (EU) restricting the export of vaccines to the UK and the United Kingdom’s movement to ban vaccine exports to the EU. It is hoped that the government will make all-out efforts to prevent disruption to the supply and demand of vaccines secured by external variables.
News directly edited by the Hankook Ilbo can also be viewed on Naver.
